Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (171-180 of 272) with videos related to

Pageof 28
Sort By:
Rheumatology (Oxford, England)|February 21, 2022
Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imagingWalter P Maksymowych, Rebecca Bolce, Gaia Gallo, et al.
Arthritis Care & Research|March 26, 2024
Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 TrialVibeke Strand, Laure Gossec, Laura C Coates, et al.
Rheumatology and Therapy|June 15, 2023
Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE StudyAtul Deodhar, Natalie J Shiff, Cinty Gong, et al.
Rheumatology and Therapy|December 22, 2020
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 StudiesXenofon Baraliakos, Filip Van den Bosch, Pedro M Machado, et al.
Annals of the Rheumatic Diseases|December 16, 2016
Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trialsCharles Peterfy, Vibeke Strand, Lu Tian, et al.
Frontiers in Immunology|March 24, 2025
Divergent B-cell and cytotoxic TNK cell activation signatures in HLA-B27-associated ankylosing spondylitis and acute anterior uveitisEisa Mahyari, Sean Davin, Kimberly Ogle, et al.
The Journal of Rheumatology|February 15, 2023
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST ProgramAtul Deodhar, Denis Poddubnyy, Proton Rahman, et al.
Dermatology and Therapy|March 7, 2024
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical TrialsRui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.
Seminars in Arthritis and Rheumatism|December 12, 2013
Proceedings of the 5th annual perspectives in rheumatic diseasesDaniel E Furst, Brian Mandell, Leonard H Calabrese, et al.
ACR Open Rheumatology|July 14, 2022
Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension StudyPhilip C Robinson, Pedro M Machado, Nigil Haroon, et al.
Pageof 28

Showing results (171-180 of 272) with videos related to

Sort By:
Pageof 28
Rheumatology (Oxford, England)|February 21, 2022
Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imagingWalter P Maksymowych, Rebecca Bolce, Gaia Gallo, et al.
Arthritis Care & Research|March 26, 2024
Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 TrialVibeke Strand, Laure Gossec, Laura C Coates, et al.
Rheumatology and Therapy|June 15, 2023
Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE StudyAtul Deodhar, Natalie J Shiff, Cinty Gong, et al.
Rheumatology and Therapy|December 22, 2020
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 StudiesXenofon Baraliakos, Filip Van den Bosch, Pedro M Machado, et al.
Annals of the Rheumatic Diseases|December 16, 2016
Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trialsCharles Peterfy, Vibeke Strand, Lu Tian, et al.
Frontiers in Immunology|March 24, 2025
Divergent B-cell and cytotoxic TNK cell activation signatures in HLA-B27-associated ankylosing spondylitis and acute anterior uveitisEisa Mahyari, Sean Davin, Kimberly Ogle, et al.
The Journal of Rheumatology|February 15, 2023
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST ProgramAtul Deodhar, Denis Poddubnyy, Proton Rahman, et al.
Dermatology and Therapy|March 7, 2024
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical TrialsRui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, et al.
Seminars in Arthritis and Rheumatism|December 12, 2013
Proceedings of the 5th annual perspectives in rheumatic diseasesDaniel E Furst, Brian Mandell, Leonard H Calabrese, et al.
ACR Open Rheumatology|July 14, 2022
Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension StudyPhilip C Robinson, Pedro M Machado, Nigil Haroon, et al.
Pageof 28